Top 5 Heal Care Companies To Own In Right Now

Top 5 Heal Care Companies To Own In Right Now: Ocera Therapeutics Inc (OCRX)

Ocera Therapeutics, Inc., formerly Tranzyme, Inc., incorporated on January 12, 1998, is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. The Company is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders. Enrollment is complete in a multinational Phase-IIb trial evaluating TZP-102 given once daily in diabetic patients with gastroparesis. The Company has initiated a second Phase-IIb trial (DIGEST) evaluating TZP-102 given prior to meals in diabetic patients with gastroparesis. On July 15, 2013, Ocera Therapeutics, Inc. merged with the Company.

Ulimorelin (Intravenous Ghrelin Agonist)

Ulimorelin is an intravenous ghrelin agonist in Phase III clinical development for the acceleration of postoperative GI recovery. Ulimorelin is designed t o accelerate the return of normal GI function in patients suffering from acute GI disorders. In addition to the ongoing trials, the Company has completed multiple trials of ulimorelin.

TZP-102 (Oral Ghrelin Agonist)

TZP-102 is an orally-administered ghrelin agonist, which it is developing for diabetic gastroparesis, an upper GI motility disorder. Gastroparesis is a debilitating, chronic condition characterized by slow or delayed gastric emptying and gastric retention that can be caused by any disease that induces neuromuscular dysfunction of the GI tract, notably diabetes.

Advisors' Opinion:

• [By Monica Gerson]

  Ocera Therapeutics (NASDAQ: OCRX) plummeted 16.01% to $13.80. Ocera Therapeutics shares have jumped 158.33% over the past 52 weeks, while the S&P 500 index has gained 23.35% in the same ! period.

• [By Jon C. Ogg]

  Ocera Therapeutics Inc. (NASDAQ: OCRX) was started as Buy with a $19.00 price target at Stifel Nicolaus. This represents 62% upside to the $11.70 closing price. This positive call is based on a best-in-class mechanism action of its lead product candidate against hepatic encephalopathy in patients with acute and chronic liver disease.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-heal-care-companies-to-own-in-right-now-3.html